Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin

ABSTRACT

Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site.

This application is a continuation application of U.S. patentapplication Ser. No. 12/056,511, filed Mar. 27, 2008, and entitled“PHARMACEUTICAL GELS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS TO ASITE BENEATH THE SKIN.” This entire disclosure is incorporated herein byreference into the present disclosure.

BACKGROUND

Localized delivery (e.g., intrathecally, intraspinally,intraarticularly, etc.) of therapeutic agents has become increasinglymore popular over the years because it has several advantages over moreconventional routes of drug delivery such as oral delivery. Localizeddelivery has the advantage of allowing the therapeutic agent to beimplanted directly at the site where drug action is needed. This becomesespecially important for drugs that have unwanted systemic side effects.

Localized delivery of therapeutic agents has the advantage of protectingthe therapeutic agent from breakdown due to harsh physiologicalenvironments (e.g., gastric and liver enzymes) and thus improves thedrug's stability in vivo. This particular feature makes this technologyparticularly attractive for the delivery of labile drugs such asproteins and peptides. Localized delivery also improves patientcompliance. For example, therapeutic agents can be encapsulated anddelivered locally allowing the drug to be released over extended periods(e.g., 6 months or longer) and hence eliminates the need for multipleinjections. This feature can improve patient compliance especially fordrugs for chronic indications, requiring frequent injections.

In the past, localized repeat delivery of therapeutic agents has beenused to treat chronic debilitating diseases such as osteoarthritis.Osteoarthritis is a chronic condition that affects millions of people inthe world, and it is a type of arthritis that is caused by the chronicbreakdown and eventual loss of cartilage in one or more joints.Osteoarthritis often affects synovial joints, such as the knees, hips,fingers, thumbs, neck, and spine. Severe forms of the disease areextremely disabling and restrict a patient's lifestyle. Localizeddelivery via intraarticular injection of corticosteroids, hyaluronan orhylan provide some short term relief in controlling the pain symptoms ofosteoarthritis.

Sciatica, another debilitating disease, can be a painful conditionassociated with the sciatic nerve which runs from the lower part of thespinal cord (the lumbar region), down the back of the leg and to thefoot. Sciatica generally begins with a herniated disc, which later leadsto local immune system activation. The herniated disc also may damagethe nerve root by pinching or compressing it, leading to additionalimmune system activation in the area. In the past, localized delivery ofcorticosteroids (e.g., epidural) has been used to provide short termrelief of the inflammation and pain associated with sciatica.

Newer methods are currently being investigated for treatment of chronicdebilitating diseases utilizing localized delivery of drug depots. Inthese treatments typically the drug depot is delivered locally to thetreatment site and the drug is released from the depot in a relativelyuniform dose over weeks, months or even years. Localized delivery ofdrug depots is becoming especially important and popular in modulatingthe immune, inflammation and/or pain responses in treatment of chronicdiseases.

Sometimes after the drug depot is implanted at the treatment site,unfortunately, the drug depot may migrate from the implant site asphysiological conditions change (e.g., repair and regeneration of cells,tissue in growth, movement at implant site, etc.). At times, this mayreduce efficacy of the drug as the drug depot migrates away from theimplant site and lodges in a distant site. If this occurs, often thedrug depot will have to be removed from the distant site and bereinserted causing additional physical and psychological trauma to apatient. In some cases, if the drug depot migrates into a joint, thedrug depot may inhibit movement. In more severe cases, if the drug depotmigrates in a blood vessel, it may restrict blood flow causing anischemic event (e.g., embolism, necrosis, infarction, etc.), which couldbe detrimental to the patient.

New drug depot compositions and methods are needed, which can easilyallow accurate and precise placement of a drug depot with minimalphysical and psychological trauma to a patient. When implanting severaldrug depots at a time, drug depot compositions and methods are neededthat accurately and precisely allow placement of the drug depot in amanner that optimizes location, accurate spacing, and drug distribution.

SUMMARY

New drug depot compositions and methods are provided, which can easilyallow accurate and precise implantation of a drug depot with minimalphysical and psychological trauma to a patient. One advantage of thedrug depot compositions and methods is that the drug depot can now beeasily delivered and adheres to the target tissue site (e.g., synovialjoint, at or near the spinal column, etc.) using a gel that hardens uponcontact with the target tissue. In this way, accurate and preciseimplantation of a drug depot in a minimally invasive procedure can beaccomplished. Another advantage, in various embodiments, is that byutilizing the gel, implantation of the drug depot can now beaccomplished without the need to suture the drug depot to the targetsite reducing physical and psychological trauma to the patient. Invarious embodiments, the gel is sprayable (utilizes “spray-a-dose”technology) and allows voids in, for example, bones to be filled in sothat the drug depot can be delivered directly to the target tissue site.In various embodiments, when several drug depots are to be implanted,the gel allows accurate placement of the drug depot in a manner tooptimize location, accurate spacing, and drug distribution.

In one exemplary embodiment, a gel for delivering a therapeutic agent toa target tissue site beneath the skin of a patient is provided, the gelbeing capable of adhering to the target tissue site and comprising oneor more biodegradable depots containing an effective amount of thetherapeutic agent, wherein the target tissue site comprises at least onemuscle, ligament, tendon, cartilage, spinal disc, spinal foraminal spacenear the spinal nerve root, facet or synovial joint, or spinal canal.

In another exemplary embodiment, a method is provided for delivering atherapeutic agent into a synovial joint of a patient, the methodcomprising inserting a cannula or needle at or near a target tissue sitein the synovial joint and spraying a gel capable of adhering to thetarget tissue site in the synovial joint, the gel comprising one or morebiodegradable depots containing an effective amount of the therapeuticagent.

In yet another exemplary embodiment, a method for delivering atherapeutic agent into a target tissue site beneath the skin isprovided, the method comprising inserting a cannula or needle at or neara target tissue site and injecting a gel capable of adhering to thetarget tissue site, the gel comprising one or more biodegradable depotscontaining an effective amount of the therapeutic agent, wherein thetarget tissue site comprises a spinal disc, spinal foraminal space nearthe spinal nerve root, facet joint, spinal canal, or bone.

Additional features and advantages of various embodiments will be setforth in part in the description that follows, and in part will beapparent from the description, or may be learned by practice of variousembodiments. The objectives and other advantages of various embodimentswill be realized and attained by means of the elements and combinationsparticularly pointed out in the description and appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

In part, other aspects, features, benefits and advantages of theembodiments will be apparent with regard to the following description,appended claims and accompanying drawings where:

FIG. 1 illustrates a side sectional view of a joint affected byosteoarthritis and delivery of an embodiment of a sprayable gelcontaining a plurality of drug depots inserted into the synovial jointvia a cannula or needle.

FIG. 2 illustrates a side sectional view of a joint affected byosteoarthritis and delivery of an embodiment of a gel containing aplurality of drug depots, which adheres and hardens after contact withthe target tissue, in this case, a synovial joint.

FIG. 3 illustrates a number of common locations within a patient thatmay be affected by osteoarthritis and locations that the pharmaceuticalgel can locally be administered thereto and used to fill voids in bone.

FIG. 4 illustrates a schematic dorsal view of the spine and sites wherethe pharmaceutical gel can locally be administered thereto.

It is to be understood that the figures are not drawn to scale. Further,the relation between objects in a figure may not be to scale, and may infact have a reverse relationship as to size. The figures are intended tobring understanding and clarity to the structure of each object shown,and thus, some features may be exaggerated in order to illustrate aspecific feature of a structure.

DETAILED DESCRIPTION

For the purposes of this specification and appended claims, unlessotherwise indicated, all numbers expressing quantities of ingredients,percentages or proportions of materials, reaction conditions, and othernumerical values used in the specification and claims, are to beunderstood as being modified in all instances by the term “about.”Accordingly, unless indicated to the contrary, the numerical parametersset forth in the following specification and attached claims areapproximations that may vary depending upon the desired propertiessought to be obtained by the present invention. At the very least, andnot as an attempt to limit the application of the doctrine ofequivalents to the scope of the claims, each numerical parameter shouldat least be construed in light of the number of reported significantdigits and by applying ordinary rounding techniques.

Notwithstanding that the numerical ranges and parameters setting forth,the broad scope of the invention are approximations, the numericalvalues set forth in the specific examples are reported as precisely aspossible. Any numerical value, however, inherently contains certainerrors necessarily resulting from the standard deviation found in theirrespective testing measurements. Moreover, all ranges disclosed hereinare to be understood to encompass any and all subranges subsumedtherein. For example, a range of “1 to 10” includes any and allsubranges between (and including) the minimum value of 1 and the maximumvalue of 10, that is, any and all subranges having a minimum value ofequal to or greater than 1 and a maximum value of equal to or less than10, e.g., 5.5 to 10.

It is noted that, as used in this specification and the appended claims,the singular forms “a,” “an,” and “the,” include plural referents unlessexpressly and unequivocally limited to one referent. Thus, for example,reference to “a drug depot” includes one, two, three or more drugdepots.

Reference will now be made in detail to certain embodiments of theinvention, examples of which are illustrated in the accompanyingdrawings. While the invention will be described in conjunction with theillustrated embodiments, it will be understood that they are notintended to limit the invention to those embodiments. On the contrary,the invention is intended to cover all alternatives, modifications, andequivalents, which may be included within the invention as defined bythe appended claims.

The headings below are not meant to limit the disclosure in any way;embodiments under any one heading may be used in conjunction withembodiments under any other heading.

New drug depot compositions and methods are provided, which can easilyallow accurate and precise implantation of a drug depot with minimalphysical and psychological trauma to the patient. The drug depotcompositions and methods provided utilize a gel that adheres to thetarget tissue site (e.g., synovial joint, at or near the spinal column,etc.), and in various embodiments, hardens on contact with the targettissue site. In this way, accurate and precise implantation of a drugdepot in a minimally invasive procedure can be accomplished. In variousembodiments, the gel avoids the need to suture the drug depot to thetarget site reducing physical and psychological trauma to the patient.In various embodiments, when several drug depots are to be implanted,the gel allows accurate placement of the drug depot in a manner tooptimize location, accurate spacing, and drug distribution. In variousembodiments, the drug depot compositions and methods utilizespray-a-dose technology that allows voids in, for example, bones to befilled in so that the drug depot can be delivered directly to the targettissue site.

Drug Depot

In various embodiments, the gel comprises a drug depot. A drug depotcomprises a physical structure to facilitate sustained release of thedrug in a desired site (e.g., a synovial joint, a disc space, a spinalcanal, a tissue of the patient, etc.). The drug depot also comprises thedrug. The term “drug” as used herein is generally meant to refer to anysubstance that alters the physiology of a the patient. The term “drug”may be used interchangeably herein with the terms “therapeutic agent”,“therapeutically effective amount”, and “active pharmaceuticalingredient” or “API”. It will be understood that a “drug” formulationmay include more than one therapeutic agent, wherein exemplarycombinations of therapeutic agents include a combination of two or moredrugs. The drug depot provides a concentration gradient of thetherapeutic agent around the depot for delivery to the site. In variousembodiments, the drug depot provides an optimal drug concentrationgradient of the therapeutic agent at a distance of up to about 1 cm toabout 5 cm from the implant site.

A “therapeutically effective amount” or “effective amount” is such thatwhen administered, the drug results in alteration of the biologicalactivity, such as, for example, inhibition of inflammation, reduction oralleviation of pain, improvement in the condition, etc. The dosageadministered to a patient can be as single or multiple doses dependingupon a variety of factors, including the drug's administeredpharmacokinetic properties, the route of administration, patientconditions and characteristics (sex, age, body weight, health, size,etc.), extent of symptoms, concurrent treatments, frequency of treatmentand the effect desired.

Examples of therapeutic agents include, those that are direct- andlocal-acting modulators of pro-inflammatory cytokines such as TNF-α andIL-1 including, but not limited to, soluble tumor necrosis factor αreceptors, any pegylated soluble tumor necrosis factor α receptor,monoclonal or polyclonal antibodies or antibody fragments orcombinations thereof. Examples of suitable therapeutic agents includereceptor antagonists, molecules that compete with the receptor forbinding to the target molecule, antisense polynucleotides, andinhibitors of transcription of the DNA encoding the target protein.Suitable examples include but are not limited to Adalimumab, Infliximab,Etanercept, Pegsunercept (PEG sTNF-R1), sTNF-R1, CDP-870, CDP-571,CNI-1493, RDP58, ISIS 104838, 1→3-β-D-glucans, Lenercept, PEG-sTNFRII FcMutein, D2E7, Afelimoinab, and combinations thereof. In otherembodiments, a therapeutic agent includes metalloprotease inhibitors,glutamate antagonists, glial cell-derived neurotropic factors (GDNF), B2receptor antagonists, Substance P receptor (NK1) antagonists such ascapsaicin and civamide, downstream regulatory element antagonisticmodulator (DREAM), iNOS, inhibitors of tetrodotoxin (TTX)-resistantNa+-channel receptor subtypes PN3 and SNS2, inhibitors of interleukinssuch as IL-1, IL-6 and IL-8, and anti-inflammatory cytokines, TNFbinding protein, onercept (r-hTBP-1), recombinant adeno-associated viral(rAAV) vectors encoding inhibitors, enhancers, potentiators, orneutralizers, antibodies, including but not limited to naturallyoccurring or synthetic, double-chain, single-chain, or fragmentsthereof. For example, suitable therapeutic agents include molecules thatare based on single chain antibodies called Nanobodies™ (Ablynx, GhentBelgium), which are defined as the smallest functional fragment of anaturally occurring, single-domain antibody. Alternatively, therapeuticagents include, agents that effect kinases and/or inhibit cell signalingmitogen-activated protein kinases (MAPK), p38 MAPK, Src or proteintyrosine kinase (PTK). Therapeutic agents include, kinase inhibitorssuch as, for example, Gleevec, Herceptin, Iressa, imatinib (STI571),herbimycin A, tyrphostin 47, erbstatin, genistein, staurosporine,PD98059, SB203580, CNI-1493, VX-50/702 (Vertex/Kissei), SB203580, BIRB796 (Boehringer Ingelheim), Glaxo P38 MAP Kinase inhibitor, RW167657(J&J), UO126, Gd, SCIO-469 (Scios), RO3201195 (Roche), Semipimod(Cytokine PharmaSciences), or derivatives thereof.

Therapeutic agents, in various embodiments, block the transcription ortranslation of TNF-α or other proteins in the inflammation cascade.Suitable therapeutic agents include, but are not limited to, integrinantagonists, alpha-4 beta-7 integrin antagonists, cell adhesioninhibitors, interferon gamma antagonists, CTLA4-Ig agonists/antagonists(BMS-188667), CD40 ligand antagonists, Humanized anti-IL-6 mAb (MRA,Tocilizumab, Chugai), HMGB-1 mAb (Critical Therapeutics Inc.), anti-IL2Rantibodies (daclizumab, basilicimab), ABX (anti IL-8 antibodies),recombinant human IL-10, or HuMax IL-15 (anti-IL 15 antibodies).

Other suitable therapeutic agents include IL-1 inhibitors, such Kineret®(anakinra) which is a recombinant, non-glycosylated form of the humaninerleukin-1 receptor antagonist (IL-1Ra), or AMG 108, which is amonoclonal antibody that blocks the action of IL-1. Therapeutic agentsalso include excitatory amino acids such as glutamate and aspartate,antagonists or inhibitors of glutamate binding to NMDA receptors, AMPAreceptors, and/or kainate receptors. Interleukin-1 receptor antagonists,thalidomide (a TNF-α release inhibitor), thalidomide analogues (whichreduce TNF-α production by macrophages), bone morphogenetic protein(BMP) type 2 and BMP-4 (inhibitors of caspase 8, a TNF-α activator),quinapril (an inhibitor of angiotensin II, which upregulates TNF-α),interferons such as IL-11 (which modulate TNF-α receptor expression),and aurin-tricarboxylic acid (which inhibits TNF-α), for example, mayalso be useful as therapeutic agents for reducing inflammation. It iscontemplated that where desirable a pegylated form of the above may beused. Examples of other therapeutic agents include NF kappa B inhibitorssuch as glucocorticoids, clonidine; antioxidants, such asdilhiocarbamate, and other compounds, such as, for example,sulfasalazine.

Specific examples of therapeutic agents suitable for use include, butare not limited to an anti-inflammatory agent, analgesic agent, orosteoinductive growth factor or a combination thereof. Anti-inflammatoryagents include, but are not limited to, salicylates, diflunisal,sulfasalazine, indomethacin, ibuprofen, naproxen, tolmetin, ketorolac,diclofenac, ketoprofen, fenamates (mefenamic acid, meclofenamic acid),enolic acids (piroxicam, meloxicam), nabumetone, celecoxib, etodolac,nimesulide, apazone, gold, sulindac or tepoxalin; antioxidants, such asdithiocarbamate, and other compounds such assulfasalazine[2-hydroxy-5-[-4-[C2-pyridinylamino)sulfonyl]azo]benzoicacid], steroids, such as fluocinolone, cortisol, cortisone,hydrocortisone, fludrocortisone, prednisone, prednisolone,methylprednisolone, triamcinolone, betamethasone, dexamethasone,beclomethasone, fluticasone or a combination thereof.

Suitable anabolic growth or anti-catabolic growth factors include, butare not limited to, a bone morphogenetic protein, a growthdifferentiation factor, a LIM mineralization protein, CDMP or progenitorcells or a combination thereof.

Suitable analgesic agents include, but are not limited to,acetaminophen, lidocaine, bupivicaine, opioid analgesics such asbuprenorphine, butotphanol, dextromoramide, dezocine,dextropropoxyphene, diamorphine, fentanyl, alfentanil, sufentanil,hydrocodone, hydromorphone, ketobemidone, levomethadyl, mepiridine,methadone, morphine, nalbuphine, opium, oxycodone, papaveretum,pentazocine, pethidine, phenoperidine, piritramide, dextropropoxyphene,remifentanil, tilidine, tramadol, codeine, dihydrocodeine, meptazinol,dezocine, eptazocine, flupirtine or a combination thereof.

Analgesics also include agents with analgesic properties, such as forexample, amitriptyline, carbamazepine, gabapentin, pregabalin,clonidine, or a combination thereof.

The depot may contain a muscle relaxant. Exemplary muscle relaxantsinclude by way of example and not limitation, alcuronium chloride,atracurium bescylate, baclofen, carbolonium, carisoprodol, chlorphenesincarbamate, chlorzoxazone, cyclobenzaprine, dantrolene, decamethoniumbromide, fazadinium, gallamine triethiodide, hexafluorenium,meladrazine, mephensin, metaxalone, methocarbamol, metocurine iodide,pancuronium, pridinol mesylate, styramate, suxamethonium, suxethonium,thiocolchicoside, tizanidine, tolperisone, tubocuarine, vecuronium, orcombinations thereof.

The depot comprises the therapeutic agent or agents and may also containother non-active ingredients. It has a multi-functional purposeincluding the carrying, stabilizing and controlling the release of thetherapeutic agent(s). The controlled release process, for example, maybe by a solution-diffusion mechanism or it may be governed by anerosion-controlled process. Typically, the depot will be a solid orsemi-solid formulation comprised of a biocompatible material, which canbe biodegradable. The term “solid” is intended to mean a rigid material,while, “semi-solid” is intended to mean a material that has some degreeof flexibility, thereby allowing the depot to bend and conform to thesurrounding tissue requirements.

In various embodiments, the depot material will be durable within thetissue site for a period of time equal to (for biodegradable components)or greater than (for non-biodegradable components) the planned period ofdrug delivery. For example, the depot material may have a melting pointor glass transition temperature close to or higher than bodytemperature, but lower then the decomposition or degradation temperatureof the therapeutic agent. However, the pre-determined erosion of thedepot material can also be used to provide for slow release of theloaded therapeutic agent(s).

In various embodiments, the depot may have a high drug loading, suchthat the therapeutic agent comprises about 0.5-99 wt % of the depot,1.0-40 wt % of the depot, 5-20 wt % of the depot, or 30-95 wt % of thedepot, or 50-95 wt % of the depot. The balance is depot material,including optional inactive materials.

In some instance, it may be desirable to avoid having to remove the drugdepot after use. In those instances, the depot may comprise abiodegradable material. There are numerous materials available for thispurpose and having the characteristic of being able to breakdown ordisintegrate over a prolonged period of time when positioned at or nearthe target tissue. As function of the chemistry of the biodegradablematerial the mechanism of the degradation process can be hydrolytical orenzymatical in nature, or both. In various embodiments, the degradationcan occur either at the surface (heterogeneous or surface erosion) oruniformly throughout the drug delivery system depot (homogeneous or bulkerosion).

A “depot” includes but is not limited to capsules, microspheres,microparticles, microcapsules, microfibers particles, nanospheres,nanoparticles, coating, matrices, wafers, pills, pellets, emulsions,liposomes, micelles, or other pharmaceutical delivery compositions.Suitable materials for the depot are ideally pharmaceutically acceptablebiodegradable and/or any bioabsorbable materials that are preferably FDAapproved or GRAS materials. These materials can be polymeric ornon-polymeric, as well as synthetic or naturally occurring, or acombination thereof.

The term “biodegradable” includes that all or parts of the drug depotand/or gel will degrade over time by the action of enzymes, byhydrolytic action and/or by other similar mechanisms in the human body.In various embodiments, “biodegradable” includes that the gel and/ordepot (e.g., microparticle, microsphere, etc.) can break down or degradewithin the body to non-toxic components after or while a therapeuticagent has been or is being released. By “bioerodible” it is meant thatthe depot and/or gel will erode or degrade over time due, at least inpart, to contact with substances found in the surrounding tissue, fluidsor by cellular action. By “bioabsorbable” it is meant that the depotand/or gel will be broken down and absorbed within the human body, forexample, by a cell or tissue. “Biocompatible” means that neither thedepot and/or gel will cause substantial tissue irritation or necrosis atthe target tissue site.

In various embodiments, the depot may comprise a bioabsorbable, abioabsorbable, and/or a biodegradable biopolymer that may provideimmediate release, sustained release or controlled release of the drug.Examples of suitable sustained release biopolymers include but are notlimited to poly(alpha-hydroxy acids), poly(lactide-co-glycolide) (PLGA),polylactide (PLA), polyglycolide (PG), polyethylene glycol (PEG)conjugates of poly(alpha-hydroxy acids), polyorthoesters, polyaspirins,polyphosphagenes, collagen, starch, pre-gelatinized starch, hyaluronicacid, chitosans, gelatin, alginates, albumin, fibrin, vitamin E analogs,such as alpha tocopheryl acetate, d-alpha tocopheryl succinate,D,L-lactide, or L-lactide, -caprolactone, dextrans, vinylpyrrolidone,polyvinyl alcohol (PVA), PVA-g-PLGA, PEGT-PBT copolymer (polyactive),methacrylates, poly(N-isopropylacrylamide), PEO-PPO-PEO (pluronics),PEO-PPO-PAA copolymers, PLGA-PEO-PLGA, PEG-PLG, PLA-PLGA, poloxamer 407,PEG-PLGA-PEG triblock copolymers, SAIB (sucrose acetate isobutyrate) orcombinations thereof.

The depot may optionally contain inactive materials such as bufferingagents and pH adjusting agents such as potassium bicarbonate, potassiumcarbonate, potassium hydroxide, sodium acetate, sodium borate, sodiumbicarbonate, sodium carbonate, sodium hydroxide or sodium phosphate;degradation/release modifiers; drug release adjusting agents;emulsifiers; preservatives such as benzalkonium chloride, chlorobutanol,phenylmercuric acetate and phenylmercuric nitrate, sodium bisulfite,sodium bisulfate, sodium thiosulfate, thimerosal, methylparaben,polyvinyl alcohol and phenylethyl alcohol; solubility adjusting agents;stabilizers; and/or cohesion modifiers. Typically, any such inactivematerials will be present within the range of 0-75 wt %, and moretypically within the range of 0-30 wt %. If the depot is to be placed inthe spinal area or joint area, in various embodiments, the depot maycomprise sterile preservative free material.

The depot can be different sizes, shapes and configurations. There areseveral factors that can be taken into consideration in determining thesize, shape and configuration of the drug depot. For example, both thesize and shape may allow for ease in positioning the drug depot at thetarget tissue site that is selected as the implantation or injectionsite. In addition, the shape and size of the system should be selectedso as to minimize or prevent the drug depot from moving afterimplantation or injection. In various embodiments, the drug depot can beshaped like a sphere, a cylinder such as a rod or fiber, a flat surfacesuch as a disc, film or sheet, and the like. Flexibility may be aconsideration so as to facilitate placement of the drug depot. Invarious embodiments, the drug depot can be different sizes, for example,the drug depot may be a length of from about 0.5 mm to 5 mm and have adiameter of from about 0.01 to about 2 mm. In various embodiments, thedrug depot may have a layer thickness of from about 0.005 to 5.0 mm,such as, for example, from 0.05 to 0.75 mm.

Radiographic markers can be included on the drug depot or gel to permitthe user to accurately position the depot or gel into the target site ofthe patient. These radiographic markers will also permit the user totrack movement and degradation of the depot at the site over time. Inthis embodiment, the user may accurately position the depot or gel inthe site using any of the numerous diagnostic imaging procedures. Suchdiagnostic imaging procedures include, for example, X-ray imaging orfluoroscopy. Examples of such radiographic markers include, but are notlimited to, barium, calcium, and/or metal beads or particles. In variousembodiments, the radiographic marker could be a spherical shape or aring around the depot.

Gel

In one exemplary embodiment, a gel for delivering a therapeutic agent toa target tissue site beneath the skin of a patient is provided, the gelbeing capable of adhering to the target tissue site and comprising oneor more biodegradable depots containing an effective amount of thetherapeutic agent, wherein the target tissue site comprises at least onemuscle, ligament, tendon, cartilage, spinal disc, spinal foraminal spacenear the spinal nerve root, facet or synovial joint, or spinal canal.

In various embodiments, the gel includes a substance having agelatinous, jelly-like, or colloidal properties at room temperature. Thegel, in various embodiments, may have the therapeutic agent dispersedthroughout it or one or more drug depots comprising the therapeuticagent may be suspended within the gel. The dispersal of the therapeuticagent may be even throughout the gel. Alternatively, the concentrationof the therapeutic agent may vary throughout it. As the biodegradablematerial of the gel or drug depot degrades at the site, the therapeuticagent is released.

In another exemplary embodiment, the gel in viscous form is loaded withone or more drug depots (e.g., microspheres loaded with a therapeuticagent), wherein the viscous gel is positioned into a synovial joint,disc space, a spinal canal, or a soft tissue surrounding the spinalcanal of a subject. The gel can also be used, in various embodiments, toseal or repair tissue. In yet another exemplary embodiment, the gel is asprayable, injectable, and/or an adherent gel that solidifies uponcontact with tissue. For example, the gel may be administered as aliquid that gels in situ at the target tissue site. In variousembodiments, the gel can comprise a two part system where a liquid isadministered and a gelling agent is added subsequently to cause theliquid to gel or harden.

In various embodiments, the gel is a hardening gel, which is separatefrom the drug depot and applied before, during or after implantation ofthe drug depot. After the gel is applied to the target site, it hardensholding the drug depot in place in this way the need to suture the depotto the target tissue site is avoided.

In various embodiments, the viscous gel is loaded with a drug depot,which delivers the therapeutic agent to the desired target tissue site(e.g., inflammed tissue, degenerative tissue, etc.) and prevents thedrug depot from being removed from that site by the venous systemiccirculation or otherwise dispersed too widely, which reduces the desiredtherapeutic effect. For example, after hours or days, the gel may beabsorbed, thereby allowing the drug depots (e.g., microspheres) to beginreleasing the therapeutic agent. The microspheres may not beginreleasing the agent until they are released from the gel. So, themicrospheres may be formed from an insoluble or inert substances, butsoluble or active once it comes into contact with the target tissuesite. Likewise, the gel may comprise a substance that dissolves ordisperses within the tissue. As the gel begins to dissolve within hoursto days, the drug depots (e.g., microspheres) are exposed to body fluidsand begin releasing their contents. So, the gel may comprise the same ordifferent material as the drug depot (e.g., POE, PEG). The gel and drugdepot can be formulated to optimize exposure time of the drug depot andrelease of the therapeutic agent from the drug depot.

In various embodiments, the gel is flowable and can be injected,sprayed, instilled, and/or dispensed to, on or in the target tissuesite. “Flow-able” means that the gel formulation is easy to manipulateand may be brushed, sprayed, dripped, injected, shaped and/or molded ator near the target tissue site as it coagulates. “Flowable” includesformulations with a low viscosity or water-like consistency to thosewith a high viscosity, such as a paste-like material. In variousembodiments, the flowability of the formulation allows it to conform toirregularities, crevices, cracks, and/or voids in the tissue site. Forexample, in various embodiments, the gel may be used to fill one or morevoids in an osteolytic lesion.

In various embodiments, the gel comprises poly(alpha-hydroxy acids),poly(lacticle-co-glycolide) (PLGA), polylactide (PLA), polyglycolide(PG), polyethylene glycol (PEG) conjugates of poly(alpha-hydroxy acids),polyorthoesters, polyaspirins, polyphosphagenes, collagen, starch,pre-gelatinized starch, hyaluronic acid, chitosans, gelatin, alginates,albumin, fibrin, vitamin E analogs, such as alpha tocopheryl acetate,d-alpha tocopheryl succinate, D,L-lactide, or L-lactide, -caprolactone,dextrans, vinylpyrrolidone, polyvinyl alcohol (PVA), PVA-g-PLGA,PEGT-PBT copolymer (polyactive), methacrylates,poly(N-isopropylacrylamide), PEO-PPO-PEO (pluronics), PEO-PPO-PAAcopolymers, PLGA-PEO-PLGA, PEG-PLG (poly(d,l-lactide-co-glycolide),PLA-PLGA, poloxamer 407, PEG-PLGA-PEG triblock copolymers, SAIB (sucroseacetate isobutyrate) or combinations thereof. These one or morecomponents allow the therapeutic agent to be released from the gel in acontrolled and/or sustained manner. For example, the gel containing thetherapeutic agent and a polymer matrix can be injected at the targettissue site and the polymer matrix breaks down over time (e.g., days,months) within the target tissue site releasing the therapeutic agent.Thus the administration of the gel can be localized and occur over aperiod of time (e.g., at least one day to about 3, 6, 9 or 12 months).

The terms “sustained release” (e.g., extended release or controlledrelease) are used herein to refer to one or more therapeutic agent(s)that is introduced into the body of a human or other mammal andcontinuously releases a stream of one or more therapeutic agents over apredetermined time period and at a therapeutic level sufficient toachieve a desired therapeutic effect throughout the predetermined timeperiod. Reference to a continuous release stream is intended toencompass release that occurs as the result of biodegradation in vivo ofthe gel and/or drug depot, or a matrix or component thereof, or as theresult of metabolic transformation or dissolution of the therapeuticagent(s) or conjugates of therapeutic agent(s).

In various embodiments, the gel and/or drug depot can be designed tocause an initial burst dose of therapeutic agent within the first 24hours after implantation. “Initial burst” or “burst effect” or “bolusdose” refers to the release of therapeutic agent from the gel and/ordepot during the first 24 hours after the gel comes in contact with anaqueous fluid (e.g., synovial fluid, cerebral spinal fluid, etc.). The“burst effect” could be due to the increased release of therapeuticagent from the gel while it is coagulating or hardening to form a solidor semi solid (rubbery) implant, while the gel is still in a flowablestate, because of its relatively fast degradation properties, orrelatively fast drug diffusion through the gel. In alternativeembodiments, the gel and/or depot is designed to avoid this initialburst effect.

In various embodiments, the gel has a pre-dosed viscosity in the rangeof about 1 to about 500 centipoise (cps), 1 to about 200 cps, or 1 toabout 100 cps. After the gel is administered to the target site, theviscosity of the gel will increase and the gel will have a modulus ofelasticity (Young's modulus) in the range of about 1×10⁴ to about 6×10⁵dynes/cm², or 2×10⁴ to about 5×10⁵ dynes/cm², or 5×10⁴ to about 5×10⁵dynes/cm².

In one embodiment, a depot comprises an adherent gel comprising atherapeutic agent that is evenly distributed throughout the gel. The gelmay be of any suitable type, as previously indicated, and should besufficiently viscous so as to prevent the gel from migrating from thetargeted delivery site once deployed; the gel should, in effect, “stick”or adhere to the targeted tissue site. The gel may, for example,solidify upon contact with the targeted tissue or after deployment froma targeted delivery system. The targeted delivery system may be, forexample, a syringe, a catheter, needle or cannula or any other suitabledevice. The targeted delivery system may inject or spray the gel into oron the targeted tissue site. The therapeutic agent may be mixed into thegel prior to the gel being deployed at the targeted tissue site. Invarious embodiments, the gel may be part of a two-component deliverysystem and when the two components are mixed, a chemical process isactivated to form the gel and cause it to stick or adhere to the targettissue. In various embodiments, the gel may also adhere to the targetedtissue site by a mechanical interdigitation with the target tissue priorto hardening. In other embodiments, the gel may adhere to the targettissue site by chemical bonding of the gel to the target tissue site(e.g., ionic bonding, covalent bonding, hydrogen bonding, electrostaticinteraction, hydrophobic, hydrophilic or other interaction with targettissue site). In still other embodiments, the gel may adhere to thetarget tissue site by a combination of chemical bonding and mechanicalinterdigitation.

In various embodiments, a gel is provided that hardens or stiffens afterdelivery. Typically, hardening gel formulations may have a pre-dosedmodulus of elasticity in the range of about 1×10⁴ to about 3×10⁵dynes/cm², or 2×10⁴ to about 2×10⁵ dynes/cm², or 5×10⁴ to about 1×10⁵dynes/cm². The post-dosed hardening gels (after delivery) may have arubbery consistency and have a modulus of elasticity in the range ofabout 1×10⁴ to about 2×10⁶ dynes/cm², or 1×10⁵ to about 7×10⁵ dynes/cm²,or 2×10⁵ to about 5×10⁵ dynes/cm².

In various embodiments, for those gel formulations that contain apolymer, the polymer concentration may affect the rate at which the gelhardens (e.g., a gel with a higher concentration of polymer maycoagulate more quickly than gels having a lower concentration ofpolymer). In various embodiments, when the gel hardens, the resultingmatrix is solid but is also able to conform to the irregular surface ofthe tissue (e.g., recesses and/or projections in bone).

The percentage of polymer present in the gel may also affect theviscosity of the polymeric composition. For example, a compositionhaving a higher percentage by weight of polymer is typically thicker andmore viscous than a composition having a lower percentage by weight ofpolymer. A more viscous composition tends to flow more slowly.Therefore, a composition having a lower viscosity may be preferred insome instances, for example when applying the formulation via spray.

In various embodiments, the molecular weight of the gel can be varied bymany methods known in the art. The choice of method to vary molecularweight is typically determined by the composition of the gel (e.g.,polymer, versus non-polymer). For example in various embodiments, whenthe gel comprises one or more polymers, the degree of polymerization canbe controlled by varying the amount of polymer initiators (e.g. benzoylperoxide), organic solvents or activator (e.g. DMPT), crosslinkingagents, polymerization agent, and/or reaction time.

Suitable gel polymers may be soluble in an organic solvent. Thesolubility of a polymer in a solvent varies depending on thecrystallinity, hydrophobicity, hydrogen-bonding and molecular weight ofthe polymer. Lower molecular weight polymers will normally dissolve morereadily in an organic solvent than high-molecular weight polymers. Apolymeric gel, which includes a high molecular weight polymer, tends tocoagulate or solidify more quickly than a polymeric composition, whichincludes a low-molecular weight polymer. Polymeric gel formulations,which include high molecular weight polymers, also tend to have a highersolution viscosity than a polymeric gel, which include a low-molecularweight polymer.

When the gel is designed to be a flowable gel, it can vary from lowviscosity, similar to that of water, to a high viscosity, similar tothat of a paste, depending on the molecular weight and concentration ofthe polymer used in the gel. The viscosity of the gel can be varied suchthat the polymeric composition can be applied to a patient's tissues byany convenient technique, for example, by brushing, spraying, dripping,injecting, or painting. Different viscosities of the gel will depend onthe technique used to apply the composition. For example, sprayingrequires a gel composition having a low viscosity.

In various embodiments, the gel has an inherent viscosity (abbreviatedas “I.V.” and units are in deciliters/gram), which is a measure of thegel's molecular weight and degradation time (e.g., a gel with a highinherent viscosity has a higher molecular weight and longer degradationtime). Typically, a gel with a high molecular weight provides a strongermatrix and the matrix takes more time to degrade. In contrast, a gelwith a low molecular weight degrades more quickly and provides a softermatrix. In various embodiments, the gel has a molecular weight, as shownby the inherent viscosity, from about 0.10 dL/g to about 1.2 dL/g orfrom about 0.10 dL/g to about 0.40 dL/g.

In various embodiments, the gel can have a viscosity of about 300 toabout 5,000 centipoise (cp). In other embodiments, the gel can have aviscosity of from about 5 to about 300 cps, from about 10 cps to about50 cps, from about 15 cps to about 75 cps at room temperature, whichallows it to be sprayed at or near the target site. The gel mayoptionally have a viscosity enhancing agent such as, for example,hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethylmethylcellulose, carboxymethylcellulose and salts thereof, Carbopol,poly(hydroxyethylmethacrylate), poly(methoxyethylmethacrylate),poly(methoxyethoxyethyl methacrylate), polymethylmethacrylate (PMMA),methylmethacrylate (MMA), gelatin, polyvinyl alcohols, propylene glycol,PEG 200, PEG 300, PEG 400, PEG 500, PEG 600, PEG 700, PEG 800, PEG 900,PEG 1000, PEG 1450, PEG 3350, PEG 4500, PEG 8000 or combinationsthereof.

The sprayability of the gel can also be controlled, among other things,by controlling the particle size distribution of the gel components. Invarious embodiments, the particle size distribution of the depotssuspended in the gel may be in the range of from about 10 μm to 100 μmso that the gel can easily be sprayed at or near the target site.

In contrast, to a sprayable gel that typically employs a low viscositypolymer, a gel with a higher viscosity may be desirable for otherapplications, for example, a gel having a putty-like consistency may bemore preferable for bone regeneration applications. In variousembodiments, when a polymer is employed in the gel, the polymericcomposition includes about 10 wt % to about 90 wt % or about 30 wt % toabout 60 wt % of the polymer.

In various embodiments, the gel is a hydrogel made of high molecularweight biocompatible elastomeric polymers of synthetic or naturalorigin. A desirable property for the hydrogel to have is the ability torespond rapidly to mechanical stresses, particularly shears and loads,in the human body.

Hydrogels obtained from natural sources are particularly appealing sincethey are more likely to be biodegradable and biocompatible for in vivoapplications. Suitable hydrogels include natural hydrogels, such as forexample, gelatin, collagen, silk, elastin, fibrin andpolysaccharide-derived polymers like agarose, and chitosan, glucomannangel, hyaluronic acid, polysaccharides, such as cross-linkedcarboxyl-containing polysaccharides, or a combination thereof. Synthetichydrogels include, but are not limited to those formed from polyvinylalcohol, acrylamides such as polyacrylic acid andpoly(acrylonitrile-acrylic acid), polyurethanes, polyethylene glycol(e.g., PEG 3350, PEG 4500, PEG 8000), silicone, polyolefins such aspolyisobutylene and polyisoprene, copolymers of silicone andpolyurethane, neoprene, nitrile, vulcanized rubber,poly(N-vinyl-2-pyrrolidone), acrylates such as poly(2-hydroxy ethylmethacrylate) and copolymers of acrylates with N-vinyl pyrolidone,N-vinyl lactams, polyacrylonitrile or combinations thereof. The hydrogelmaterials may further be cross-linked to provide further strength asneeded. Examples of different types of polyurethanes includethermoplastic or thermoset polyurethanes, aliphatic or aromaticpolyurethanes, polyetherurethane, polycarbonate-urethane or siliconepoly-ether-urethane, or a combination thereof.

In various embodiments, rather than directly admixing the therapeuticagent into the gel, microspheres may be dispersed within the gel, themicrospheres loaded with the therapeutic agent. In one embodiment, themicrospheres provide for a sustained release of the therapeutic agent.In yet another embodiment, the gel, which is biodegradable, prevents themicrospheres from releasing the therapeutic agent; the microspheres thusdo not release the therapeutic agent until they have been released fromthe gel. For example, a gel may be deployed around a target tissue site(e.g., a nerve root). Dispersed within the gel are a plurality ofmicrospheres that encapsulate the desired therapeutic agent. Certain ofthese microspheres degrade once released from the gel, thus releasingthe therapeutic agent.

Microspheres, much like a fluid, may disperse relatively quickly,depending upon the surrounding tissue type, and hence disperse thetherapeutic agent. In some situations, this may be desirable; in others,it may be more desirable to keep the therapeutic agent tightlyconstrained to a well-defined target site. The present invention alsocontemplates the use of adherent gels to so constrain dispersal of thetherapeutic agent. These gels may be deployed, for example, in a discspace, in a spinal canal, or in surrounding tissue, or in a joint space,such as a synovial cavity. In this embodiment the gel is an adherentand/or settable gel in order to stay in place within a joint space.

Cannula or Needle

It will be appreciated by those with skill in the art that the gel canbe administered to the target site using a cannula or needle that can bea part of a drug delivery device e.g., a syringe, a gun drug deliverydevice, or any medical device suitable for the application of a drug toa targeted organ or anatomic region. The cannula or needle of the drugdepot device is designed to cause minimal physical and psychologicaltrauma to the patient.

Cannulas or needles include tubes that may be made from materials, suchas for example, polyurethane, polyurea, polyether(amide), PEBA,thermoplastic elastomeric olefin, copolyester, and styrenicthermoplastic elastomer, steel, aluminum, stainless steel, titanium,metal alloys with high non-ferrous metal content and a low relativeproportion of iron, carbon fiber, glass fiber, plastics, ceramics orcombinations thereof. The cannula or needle may optionally include oneor more tapered regions. In various embodiments, the cannula or needlemay be beveled. The cannula or needle may also have a tip style vitalfor accurate treatment of the patient depending on the site forimplantation. Examples of tip styles include, for example, Trephine,Cournand, Veress, Huber, Seldinger, Chiba, Francine, Bias, Crawford,deflected tips, Hustead, Lancet, or Tuohey. In various embodiments, thecannula or needle may also be non-coring and have a sheath covering itto avoid unwanted needle sticks.

The dimensions of the hollow cannula or needle, among other things, willdepend on the site for implantation. For example, the width of theepidural space is only about 3-5 mm for the thoracic region and about5-7 mm for the lumbar region. Thus, the needle or cannula, in variousembodiments, can be designed for these specific areas. In variousembodiments, the cannula or needle may be inserted using atransforaminal approach in the spinal foramen space, for example, alongan inflammed nerve root and the drug depot implanted at this site fortreating the condition. Typically, the transforaminal approach involvesapproaching the intervertebral space through the intervertebralforamina.

Some examples of lengths of the cannula or needle may include, but arenot limited to, from about 50 to 150 mm in length, for example, about 65mm for epidural pediatric use, about 85 mm for a standard adult andabout 110 mm for an obese adult patient. The thickness of the cannula orneedle will also depend on the site of implantation. In variousembodiments, the thickness includes, but is not limited to, from about0.05 to about 1.655. The gauge of the cannula or needle may be thewidest or smallest diameter or a diameter in between for insertion intoa human or animal body. The widest diameter is typically about 14 gauge,while the smallest diameter is about 25 gauge. In various embodimentsthe gauge of the needle or cannula is about 18 to about 22 gauge.

In various embodiments, like the drug depot and/or gel, the cannula orneedle includes dose radiographic markers that indicate location at ornear the site beneath the skin, so that the user may accurately positionthe depot at or near the site using any of the numerous diagnosticimaging procedures. Such diagnostic imaging procedures include, forexample, X-ray imaging or fluoroscopy. Examples of such radiographicmarkers include, but are not limited to, barium, calcium phosphate,and/or metal beads or particles.

In various embodiments, the needle or cannula may include a transparentor translucent portion that can be visualizable by ultrasound,fluoroscopy, x-ray, or other imaging techniques. In such embodiments,the transparent or translucent portion may include a radiopaque materialor ultrasound responsive topography that increases the contrast of theneedle or cannula relative to the absence of the material or topography.

The drug depot, gel, and/or medical device to administer the drug may besterilizable. In various embodiments, one or more components of the drugdepot, gel, and/or medical device to administer the drug are sterilizedby radiation in a terminal sterilization step in the final packaging.Terminal sterilization of a product provides greater assurance ofsterility than from processes such as an aseptic process, which requireindividual product components to be sterilized separately and the finalpackage assembled in a sterile environment.

Typically, in various embodiments, gamma radiation is used in theterminal sterilization step, which involves utilizing ionizing energyfrom gamma rays that penetrates deeply in the device. Gamma rays arehighly effective in killing microorganisms, they leave no residues norhave sufficient energy to impart radioactivity to the device. Gamma rayscan be employed when the device is in the package and gammasterilization does not require high pressures or vacuum conditions,thus, package seals and other components are not stressed. In addition,gamma radiation eliminates the need for permeable packaging materials.

In various embodiments, electron beam (e-beam) radiation may be used tosterilize one or more components of the device. E-beam radiationcomprises a form of ionizing energy, which is generally characterized bylow penetration and high-dose rates. E-beam irradiation is similar togamma processing in that it alters various chemical and molecular bondson contact, including the reproductive cells of microorganisms. Beamsproduced for e-beam sterilization are concentrated, highly-chargedstreams of electrons generated by the acceleration and conversion ofelectricity. E-beam sterilization may be used, for example, when thedrug depot is included in a gel.

Other methods may also be used to sterilize the gel, depot and/or one ormore components of the device, including, but not limited to, gassterilization, such as, for example, with ethylene oxide or steamsterilization.

In various embodiments, a kit is provided which may include additionalparts along with the gel and/or drug depot, medical device combinedtogether to be used to implant the gel and/or drug depot. The kit mayinclude the drug depot device in a first compartment. The secondcompartment may include a canister holding the gel and/or drug depot tobe sprayed at the target site, and any other instruments needed for thelocalized drug delivery. A third compartment may include gloves, drapes,wound dressings and other procedural supplies for maintaining sterilityof the implanting process, as well as an instruction booklet. A fourthcompartment may include additional cannulas and/or needles. Each toolmay be separately packaged in a plastic pouch that is radiationsterilized. A cover of the kit may include illustrations of theimplanting procedure and a clear plastic cover may be placed over thecompartments to maintain sterility.

Drug Delivery

In various embodiments, a method for delivering a therapeutic agent intoa synovial joint of a patient is provided, the method comprisinginserting a cannula at or near a target tissue site in the synovialjoint and implanting the drug depot at the target site beneath the skinof the patient and brushing, spraying, dripping, injecting, or paintingthe gel in the target site to hold or have the drug depot adhere to thetarget site. In this way unwanted migration of the drug depot away fromthe target site is reduced or eliminated.

In various embodiments, to administer the gel having the drug depotdispersed therein to the desired site, first the cannula or needle canbe inserted through the skin and soft tissue down to the target tissuesite and the gel administered (e.g., brushed, sprayed, dripped,injected, or painted, etc.) at or near the target site. In thoseembodiments where the drug depot is separate from the gel, first thecannula or needle can be inserted through the skin and soft tissue downto the site of injection and one or more base layer(s) of gel can beadministered to the target site. Following administration of the one ormore base layer(s), the drug depot can be implanted on or in the baselayer(s) so that the gel can hold the depot in place or reducemigration. If required a subsequent layer or layers of gel can beapplied on the drug depot to surround the depot and further hold it inplace. Alternatively, the drug depot may be implanted first and then thegel placed (e.g., brushed, sprayed, dripped, injected, or painted, etc.)around the drug depot to hold it in place. By using the gel, accurateand precise implantation of a drug depot can be accomplished withminimal physical and psychological trauma to the patient. The gel alsoavoids the need to suture the drug depot to the target site reducingphysical and psychological trauma to the patient.

In various embodiments, when the target site comprises a joint or spinalregion, a portion of fluid (e.g., synovial fluid, spinal fluid, etc.)can be withdrawn from the target site through the cannula or needlefirst and then the gel administered (e.g., brushed, sprayed, dripped,injected, or painted, etc.). The target site will re-hydrate (e.g.,replenishment of fluid) and this aqueous environment will cause the drugto be released from the depot or the gel.

The gel may be used for localized delivery of the therapeutic agent tothe patient to treat a disease or condition such as for example,osteoarthritis, rheumatoid arthritis, sciatica, carpal tunnel syndrome,lower back pain, lower extremity pain, upper extremity pain, cancer,tissue pain and pain associated with injury or repair of cervical,thoracic, and/or lumbar vertebrae or intervertebral discs, rotator cuff,articular joint, TMJ, tendons, ligaments, muscles, and the like. Invarious embodiments, the gel may also be used to repair tissue as welldeliver a therapeutic agent.

Patients include a biological system to which a treatment can beadministered. A biological system can include, for example, anindividual cell, a set of cells (e.g., a cell culture), an organ, or atissue. Additionally, the term “patient” can refer to animals,including, without limitation, humans.

Treating or treatment of a disease refers to executing a protocol, whichmay include administering one or more drugs to a patient (human orotherwise), in an effort to alleviate signs or symptoms of the disease.Alleviation can occur prior to signs or symptoms of the diseaseappearing, as well as after their appearance. Thus, “treating” or“treatment” includes “preventing” or “prevention” of disease. Inaddition, “treating” or “treatment” does not require completealleviation of signs or symptoms, does not require a cure, andspecifically includes protocols that have only a marginal effect on thepatient.

“Localized” delivery includes, delivery where one or more drugs aredeposited within a tissue, for example, a nerve root of the nervoussystem or a region of the brain, or in close proximity (within about 10cm, or preferably within about 5 cm, for example) thereto. “Targeteddelivery system” provides delivery of one or more drugs depots, gels ordepot dispersed in the gel having a quantity of therapeutic agent thatcan be deposited at or near the target site as needed for treatment ofpain, inflammation or other disease or condition.

In various embodiments, the gel may be used to treat rheumatoidarthritis (RA) and/or osteoarthritis by inserting a cannula at or near atarget tissue site and implanting the drug depot at the target sitebeneath the skin of the patient and brushing, spraying, dripping,injecting, or painting the gel at the target site to hold or have thedrug depot adhere to the target site. In this way unwanted migration ofthe drug depot away from the target site is reduced or eliminated.

RA is a chronic systemic disease characterized by progressive jointdeformity and joint destruction in which cytokines play a centralpathogenic role. The clinical course of RA is variable and often shows aremitting pattern. Three forms of RA can be distinguished: mild,self-limiting disease; mildly progressive disease; and aggressivedisease, which is difficult to control with medication, and ischaracterized by functional decline and radiologic deterioration of thejoints, e.g., joint space narrowing and erosions. In accordance with thesystemic nature of RA, there are extra-articular manifestations, whichinclude vasculitis, alveolitis, and ocular disease. Onset of RA is ofteninsidious with fatigue, anorexia, generalized weakness, and vaguemusculoskeletal symptoms. Specific symptoms appear later. Severaljoints, usually in a symmetrical fashion, are affected. Most often theseare joints of the hands, wrists, knees, and feet. Joints are painful andswollen, and motion is limited. With persistent inflammation, a varietyof deformities develop which include most typically radial deviation ofthe wrist and hyperextension or flexion of the proximal interphalangealjoints; other deformities occur as well. Atrophy of skeletal muscle setsin. In approximately 20 to 30% of all patients, there is development ofrheumatoid nodules on periarticular structures or sites of trauma, butthey are usually of limited clinical significance. The nodules may befound in other structures such as the pleura or the meninges. Laboratoryfindings may include elevation of erythrocyte sedimentation rate (ESR)and C-reactive protein (CRP) along with rheumatoid factor. Rheumatoidfactor is an autoantibody against the Fc portion of IgG found in morethan two-thirds of all patients. High titers of rheumatoid factor are agood indicator of disease activity. Mild anemia (normochromic,normocytic) and eosinophilia may be present as well. With progression ofthe disease, X-ray abnormalities such as general deformity,juxta-articular osteopenia, loss of articular cartilage, and boneerosion become more evident.

In one exemplary embodiment, the gel is utilized to treat osteoarthritis(OA), which is the most common form of arthritis in Western populations.Knee OA, characterized clinically by pain and functional disability, isthe leading cause of chronic disability among the elderly in the US.Risk factors for OA include age, gender, race, trauma, repetitivestress/joint overload, muscle weakness, and genetic factors.Pathologically, the most striking changes in OA are focal loss ofarticular cartilage and marginal and central new bone formation.However, OA is not simply a disease of articular cartilage and thesubchondral bone. Rather, it is a disease of the synovial joint, withalterations also found in the synovium, capsule, ligaments,periarticular muscle, and sensory nerves.

Although OA was once considered a non-inflammatory arthropathy, patientsoften present with signs and symptoms consistent with local inflammationand synovitis, and inflammation and inflammatory mediators play a rolein the joint destruction associated with OA as well as in pain. Bothchondrocytes and synovium in OA can produce proinflammatory cytokines,including IL-1β, which can alter cartilage homeostasis in favor ofcartilage degradation. For example, IL-1β appears to be a major factorstimulating matrix metalloproteinase synthesis and other cartilagecatabolic responses in OA.

FIG. 1 illustrates one embodiment of the effect of osteoarthritis on thejoint 10. Osteoarthritis causes the cartilage 13 to become worn awayfrom the ends of the bones 11, 12. Fragments of cartilage may break offfrom the bones and become suspended in the synovial fluid 16. Bone spurs(20 in FIG. 2) may grow out from the edge of the bones 11 and 12.Osteoarthritis may also cause the synovial membrane 15 that produces asynovial fluid 16 to nourish and lubricate the cartilage 13 to producean increased amount of synovial fluid 16. Altogether, the joint 10 maybecome swollen and/or feel stiff and sore. Muscles 17, connectivetendons 18, and other tissue (e.g., ligaments) surround the jointcapsule 14 and keep the bones 11, 12 stable and allow the joint 10 tobend and move. However, symptoms become worse and debilitating as thedisease progresses. To treat the diseased joint, the gel 22 can beadministered locally at the target site utilizing a cannula or needle 24that penetrates beneath the skin to the target site 22. In thisembodiment, the gel contains the depot suspended in it and the gel issprayed at the target site (shown at or near the osteolytic lesions). Itwill be understood that some synovial fluid 16 may be withdrawn from thejoint 10 and the gel added before, during, or after the synovial fluidis withdrawn so that as the joint re-hydrates, the therapeutic agentwill be released as the fluid contacts the drug depot. The gel may alsobe placed at other target sites (e.g., by the meniscus or cartilagesurface) and the drug released. In this way, accurate and preciseimplantation of a drug depot in a minimally invasive procedure can beaccomplished. In various embodiments, the gel avoids the need to suturethe drug depot to the target site reducing physical and psychologicaltrauma to the patient. In various embodiments, when several drug depotsare to be implanted, the gel allows accurate placement of the drug depotin a manner to optimize location, accurate spacing, and drugdistribution.

FIG. 2 illustrates one embodiment of the effect of osteoarthritis on thejoint 10. Osteoarthritis causes the cartilage 13 to become worn awayfrom the ends of the bones 11 and 12. Fragments of cartilage may breakoff from the bones and become suspended in the synovial fluid 16. Bonespurs (20 in FIG. 2) may grow out from the edge of the bones 11 and 12.Osteoarthritis may also cause the synovial membrane 15 that produces asynovial fluid 16 to nourish and lubricate the cartilage 13 to producean increased amount of synovial fluid 16. Altogether, the joint 10 maybecome swollen and/or feel stiff and sore. Muscles 17, connectivetendons 18, and other tissue (e.g., ligaments) surround the jointcapsule 14 and keep the bones 11 and 12 stable and allow the joint 10 tobend and move. However, symptoms become worse and debilitating as thedisease progresses. To treat the diseased joint, the gel can beadministered locally at the target site utilizing a cannula or needlethat penetrates beneath the skin to the target site. In this embodiment,the gel comprises the depot suspended in the gel and the gel is sprayednear the target site (shown near the osteolytic lesions). In thisembodiment, the gel has adhering and hardening characteristics 26 andadheres and hardens in an area that does not interfere with movement ofthe joint and is away from the articular surfaces of the joint. As thesynovial fluid contacts the hardening gel, the therapeutic agentsuspended therein is released.

FIG. 3 illustrates a number of common locations within a patient thatmay be affected by osteoarthritis. It will be recognized that thelocations illustrated in FIG. 3 are merely exemplary of the manydifferent locations within a patient that may be affected byosteoarthritis. For example, osteoarthritis may affect a patient's knees21, hips 22, fingers 23, thumbs 24, neck 25, and spine 26.Osteoarthritis in the hips 22 can cause pain, stiffness, and severedisability. Patients may feel the pain in their hips 22, groin, innerthigh, buttocks, or knees.

Osteoarthritis in the fingers 23 may cause the fingers 23 to becomeenlarged and gnarled. The disease may cause small, bony knobs to appearon the end joints of the fingers 23. These knobs are referred to asHeberden's nodes. Similar knobs, called Bouchard's nodes, can appear onthe middle joints of the fingers 23. Affected fingers 23 may ache or bestiff and numb. More women than men suffer from osteoarthritis in thefingers 23, and they develop it especially after menopause. The base ofthe thumb joint 24 may also be similarly affected by osteoarthritis.

Osteoarthritis in the neck 25 and spine 26 may cause stiffness and painin the neck or in the lower back. It may also cause weakness or numbnessof the arms or legs. Osteoarthritis in the neck 25 and spine 26 is oftendebilitating and may result in the patient being bed-ridden. To treatthe diseased sites of osteoarthritis, the gel can be administeredlocally at the target sites discussed above utilizing a cannula orneedle that penetrates beneath the skin to the target site.

In various embodiments, the gel is used to treat or manage pain, orother diseases or conditions of the patient. Pain includes acute painand neuropathic pain. Acute pain refers to pain experienced when tissueis being damaged or is damaged (e.g., injury, infection, etc.). Ascontrasted to acute pain, neuropathic pain serves no beneficial purpose.Neuropathic pain results when pain associated with an injury orinfection continues in an area once the injury or infection hasresolved. Sciatica provides an example of pain that can transition fromacute to neuropathic pain. Sciatica refers to pain associated with thesciatic nerve which runs from the lower part of the spinal cord (thelumbar region), down the back of the leg and to the foot. Sciaticagenerally begins with a herniated disc. The herniated disc itself leadsto local immune system activation. The herniated disc also may damagethe nerve root by pinching or compressing it, leading to additionalimmune system activation in the area.

The term “pain management medication” includes one or more therapeuticagents that are administered to prevent, alleviate or remove painentirely. These include anti-inflammatory agents, muscle relaxants,analgesics, anesthetics, narcotics, and so forth, and combinationsthereof.

One exemplary embodiment where the gel is suitable for use in painmanagement (e.g., neuropathic pain management) and/or to treatconditions (e.g., sciatica) is illustrated in FIG. 4. Schematicallyshown in FIG. 4 is a dorsal view of the spine and sites where the gelcontaining the drug depot or the drug depot held in position by the gelmay be inserted using a cannula or needle beneath the skin 34 to aspinal site 32 (e.g., spinal disc space, spinal canal, soft tissuesurrounding the spine, nerve root, etc.) and one or more drug depots 28and 32 are delivered to various sites along the spine. In this way, whenseveral drug depots are to be implanted, the gel allows accurateplacement of the drug depot in a manner to optimize location, accuratespacing, and drug distribution.

Although the spinal site is shown, as described above, the gel can beused to deliver a drug depot to any site beneath the skin, including,but not limited to, at least one muscle, ligament, tendon, cartilage,synovial joint, spinal disc, spinal foraminal space, near the spinalnerve root, facet joint, or spinal canal.

In various embodiments, the gel may have the therapeutic agent suspendedtherein and deployed around a targeted tissue site (e.g., a nerve root).The gel, either viscous or solid once deployed, keeps the therapeuticagent closely bound to target site (e.g., a nerve root) providing atherapeutically effective dosage of the therapeutic agent to the targetsite, with the dosage gradient rapidly falling off outside of the regionof the gel. The therapeutic agent is therefore tightly targeted to thedesired tissue site.

It will be apparent to those skilled in the art that variousmodifications and variations can be made to various embodimentsdescribed herein without departing from the spirit or scope of theteachings herein. Thus, it is intended that various embodiments coverother modifications and variations of various embodiments within thescope of the present teachings.

What is claimed is:
 1. A liquid gel for delivering a therapeutic agentto a target tissue site beneath the skin of a patient, the gel beingcapable of adhering to the target tissue site and comprising one or morebiodegradable depots containing an effective amount of the therapeuticagent, wherein the target tissue site comprises at least one muscle,ligament, tendon, cartilage, spinal disc, spinal foraminal space nearthe spinal nerve root, facet or synovial joint, or spinal canal, and thegel has a pre-dosed modulus of elasticity in the range of about 1×10⁴ toabout 3×10⁵ dynes/cm², and a post-dosed modulus of elasticity in therange of 1×10⁵ to about 7×10⁵ dynes/cm².
 2. A gel for delivering atherapeutic agent according to claim 1, wherein the gel is sprayable andhardens after contacting the target tissue site.
 3. A gel for deliveringa therapeutic agent according to claim 1, wherein the therapeutic agentcomprises an anti-inflammatory agent, an analgesic agent, a skeletalmuscle relaxant, a growth factor, an osteoinductive anabolic growthfactor, an anti-catabolic growth factor or a combination thereof.
 4. Agel for delivering a therapeutic agent according to claim 1, wherein thetherapeutic agent is encapsulated in a plurality of depots comprisingmicroparticles, microspheres, microcapsules, and/or microfiberssuspended in the gel.
 5. A gel for delivering a therapeutic agentaccording to claim 4, wherein the gel further comprises a bolus dose ofthe therapeutic agent suspended in the gel to provide an immediaterelease of the therapeutic agent and the effective amount of thetherapeutic agent is encapsulated in the plurality of microparticles,microspheres, microcapsules, microfibers, and/or depot particles toprovide sustained release of the therapeutic agent over time.
 6. A gelfor delivering a therapeutic agent according to claim 1, wherein the gelcomprises a hydrogel.
 7. A gel for delivering a therapeutic agentaccording to claim 1, wherein the gel comprises a radiographic markeradapted to assist in radiographic imaging.
 8. A gel for delivering atherapeutic agent according to claim 7, wherein the radiographic markercomprises barium, calcium, and/or metal beads.
 9. A method fordelivering a therapeutic agent into a synovial joint of a patient, themethod comprising inserting a cannula at or near a target tissue site inthe synovial joint and spraying a gel capable of adhering to the targettissue site in the synovial joint, the gel comprising one or morebiodegradable depots containing an effective amount of the therapeuticagent, wherein said gel is the liquid gel of claim
 1. 10. A method fordelivering a therapeutic agent according to claim 9, wherein the gelhardens after contacting the target tissue site.
 11. A method fordelivering a therapeutic agent according to claim 9, wherein thetherapeutic agent comprises an anti-inflammatory agent, an analgesicagent, a skeletal muscle relaxant, a growth factor, an osteoinductiveanabolic growth factor, an anti-catabolic growth factor or a combinationthereof.
 12. A method for delivering a therapeutic agent according toclaim 9, wherein the therapeutic agent is encapsulated in a plurality ofmicroparticles, microspheres, microcapsules, microfibers, and/or depotparticles suspended in the gel.
 13. A method for delivering atherapeutic agent according to claim 12, wherein the gel furthercomprises a bolus dose of the therapeutic agent suspended in the gel toprovide an immediate release of the therapeutic agent and the effectiveamount of the therapeutic agent is encapsulated in the plurality ofmicrospheres, microcapsules and/or microfibers to provide sustainedrelease of the therapeutic agent over time.
 14. A method for deliveringa therapeutic agent according to claim 9, wherein the gel comprisespolyethylene glycol.
 15. A method for delivering a therapeutic agentaccording to claim 9, wherein the target site comprises at least onemeniscus, cartilage, or inside of a joint capsule.
 16. A method fordelivering a therapeutic agent into a target tissue site beneath theskin, the method comprising inserting a cannula at or near a targettissue site and injecting a gel capable of adhering to the target tissuesite, the gel comprising one or more biodegradable depots containing aneffective amount of the therapeutic agent, wherein the target tissuesite comprises a spinal disc, spinal foraminal space near the spinalnerve root, facet joint, spinal canal, or bone, wherein said gel is theliquid gel of claim
 1. 17. A method for delivering a therapeutic agentaccording to claim 16, wherein the gel hardens after contacting thetarget tissue site.
 18. A method for delivering a therapeutic agentaccording to claim 16, wherein the therapeutic agent comprises ananti-inflammatory agent, an analgesic agent, a skeletal muscle relaxant,a growth factor, an osteoinductive anabolic growth factor,anti-catabolic growth factor or a combination thereof.
 19. A method fordelivering a therapeutic agent according to claim 16, wherein the gelfills a void in an osteolytic lesion.
 20. A gel for delivering atherapeutic agent according to claim 1, wherein the gel furthercomprises a viscosity enhancing agent.